Solasia Pharma K.K.
| Industry | PHARMACEUTICAL |
| Market Segment | Growth |
| Accounting | IFRS |
| Currency | JPY |
| Fiscal Year | 2024 |
Solasia Pharma K.K. engages in the development and marketing of oncology drugs in Japan and other Asian countries. The company offers Episil, an oral liquid for oral mucositis/stomatitis; and DARVIAS, an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma. It also develops Sancuso for chemotherapy induced nausea and vomiting; SP-04, which is in preclinical trial development to treat chemotherapy peripheral neuropathy; and SP-05 for the treatment of colorectal cancer. The company was founded in 2006 and is based in Tokyo, Japan.
Full charting with technical indicators, candlestick, and more.
About Solasia Pharma K.K.
Solasia Pharma K.K. engages in the development and marketing of oncology drugs in Japan and other Asian countries. The company offers Episil, an oral liquid for oral mucositis/stomatitis; and DARVIAS, an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma. It also develops Sancuso for chemotherapy induced nausea and vomiting; SP-04, which is in preclinical trial development to treat chemotherapy peripheral neuropathy; and SP-05 for the treatment of colorectal cancer. The company was founded in 2006 and is based in Tokyo, Japan.
| Ticker | 4597 |
| Exchange | TSE |
| Sector | Pharmaceutical |
| Industry | PHARMACEUTICAL |